A Randomized, Double-Blind, Single Ascending Dose Study to Identify a Safe and Non-Psychedelic Dose of Psilocybin

This study aims to systematically explore the effects of psilocybin over a range of very low dose.

The study is being conducted by Diamond Therapeutics and BioPharma Services.

Visit trial
Status Planned
Results Published
Start date 01 December 2021
End date 01 June 2022
Chance of happening 70%
Design Open
Type Observational
Generation First
Participants 20
Sex All
Therapy No

Trial Details



NCT Number PA4

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.